Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor Empagliflozin
Livia Stanger(University of Michigan), Michael Holinstat(Thomas Jefferson University), Bertram Pitt(Bayer (Germany)), Pooja Yalavarthi(University of Michigan), Mariane Flores(University of Michigan), David Creen(University of Michigan)
Cited by 5
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
The Seattle Heart Failure Model
|Circulation|2006|2k